Medications for Parathyroid Cancer
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Parathyroid Cancer.
Found 2 Approved Drugs for Parathyroid Cancer
Sensipar
Generic Name
Cinacalcet
Sensipar
Generic Name
Cinacalcet
Form: Tablet
Method of administration: Oral
FDA approval date: April 04, 2004
Classification: Calcium-sensing Receptor Agonist
Sensipar is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.
Parsabiv
Generic Name
Etelcalcetide
Parsabiv
Generic Name
Etelcalcetide
Form: Injection
Method of administration: Intravenous
FDA approval date: April 03, 2017
Classification: Calcium-sensing Receptor Agonist
PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. PARSABIV is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ( 1 ) Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations. Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis and is not recommended for use in these populations.
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances